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Introduction
Raynauds phenomenon (RP) can be the first symptom of
a connective tissue disease in children, in particular
juvenile systemic scleroderma (JSSC) or systemic lupus
erythematosis (SLE). However, the prevalence of RP in
healthy school children has been shown to be as high as
15%[1]. There are currently no guidelines or agreed
management strategies amongst Paediatric Rheumatolo-
gists on how to differentiate primary from secondary RP
or how often patients require evaluation.
Objectives
To develop consensus standards for good clinical prac-
tice for children with RP.
Methods
A consensus meeting was organized in the frame of the
PRES scleroderma working group. A nominal group
technique was used. 75% consensus was defined as
agreement.
Results
1. All patients with RP should be screened with an ANA
test.
2. All ANA positive patients should be screened for
scleroderma-specific antibodies (e.g. anti-SCL 70 and
anti-centromere antibodies).
3. All patients with RP should be investigated by capil-
laroscopy. Capillaroscopy will be classified into “normal”,
“aspecific changes” or “scleroderma pattern”.
4. All patients who have additional symptoms pointing
to a definite connective tissue disease should be evalu-
ated according to disease specific guidelines.
5. ANA-negative and capillaroscopy-negative patients
should be followed-up at least every 6 months.
6. ANA positive patients without disease-specific anti-
bodies and with negative capillaroscopy findings should
be followed-up at least every 6 months.
7. ANA and disease-specific antibody positive patients
should have organ specific evaluation according to
symptoms, examination and relevant to that particular
disease e.g. patients who are ANA and Scl-70 positive
may need organ specific evaluation for JSSC as per the
Juvenile systemic sclerosis inception cohort protocol
(http://www.juvenile-scleroderma.com).
8. ANA-positive patients, who have no disease specific
antibody but have positive capillaroscopy results, should
be followed-up at least every 3 months.
9. ANA-negative patients with positive capillaroscopy
result should be followed-up at least every 6 months.
10. The group could not reach an agreement regarding
treatment, due to a lack of data for the paediatric age
group. The group agreed that implementation of adult
recommendations for paediatric care might be reason-
able, but robust paediatric trials are needed.
Conclusion
The group made a suggestion for a standard of good
clinical practice for RP in children. Our aim is that this
will facilitate a large multicentre prospective follow-up
study of children with RP.
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